neuritic plaque


Also found in: Encyclopedia.

neu·rit·ic plaque

a spheric mass primarily composed of amyloid fibrils and interwoven neuronal processes, frequently, although not exclusively, observed in Alzheimer disease.

neuritic plaque

[noo͡rit′ik]
an extracellular deposit consisting of beta-amyloid protein mixed with branches of dying nerve cells in the brain of a patient with Alzheimer's disease.

senile plaque

A histologic finding consisting of a core of extracellular amyloid with an amyloidogenic fragment (betaA4) derived from amyloid precursor protein, surrounded by a tangled spherical mass of argyrophilic cholinergic neuritis (axons/dendrites) seen in the grey matter (neocortex, hippocampus, amygdala, less commonly, basal ganglia and elsewhere) in the brains of older persons, but markedly increased in Alzheimer’s disease.

se·nile plaque

(sen'il plak)
A spheric mass composed primarily of amyloid fibrils and interwoven neuronal processes, frequently, although not exclusively, observed in Alzheimer disease.
Synonym(s): neuritic plaque.
References in periodicals archive ?
Amyvid(TM) (Florbetapir F-18 Injection), Lilly's FDA-approved radioactive PET diagnostic agent for the estimation of beta-amyloid neuritic plaque density in the brain, will be one diagnostic agent available for use in the study.
This opinion recommends the granting of a marketing authorisation for VIZAMYL (Flutemetamol F18 injection), a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer s disease (AD) and other causes of cognitive impairment.
It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline.
For instance, Sojkova et al reported that in 6 participants, though there was agreement between in-vivo imaging and a neuritic plaque score for those patients with high or negligible A[beta] levels in vivo, only limited agreement was observed for those with intermediate levels of A[beta], emphasizing the need for better understanding of the correlation between imaging and pathologic assessment.
NeuraCeq(TM) is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment.
Yet the same agency is challenging the value of the only technology approved by the Food and Drug Administration for estimating beta-amyloid neuritic plaque density in the living brain.
or other cognitive disorder since neuritic plaque deposition in grey
They studied mice that carried a genetic mutation for promoting increased amounts of amyloid beta, a protein fragment found within the telltale neuritic plaque, or "hardening of the brain," seen in Alzheimer's disease.
One notion is that accumulation of amyloid, a protein substance in neuritic plaque, may cause damage to neurons.
is that neuritic plaque formation may be a result of overcompensation to replace degenerating nerves through accelerated nerve growth.
Food and Drug Administration (FDA) approval of Neuraceq for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline.